Spanish Registry of treatment efficacy against SARS-CoV-2 COVID-19 (RER-FAR-COVID-19)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/34344
• EU PAS number:
  EUPAS34343
• Study ID:
  34344
• Official title and acronym:
  Spanish Registry of treatment efficacy against SARS-CoV-2 COVID-19 (RER-FAR-COVID-19)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  Evaluated the effectiveness of pharmacotherapy used in the treatment of cases of SARS-CoV2 coronavirus infection, whom have required hospital admission in Spain during the pandemic declared in March 2020.
• Study status:
  Planned

Research institution and networks

Institutions

Spanish Society of Hospital Pharmacy

Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices, AEMPS)

Spain

Study timelines

Date when funding contract was signed

Planned: 30/03/2020

Study start date

Planned: 30/03/2020

Data analysis start date

Planned: 03/04/2020

Date of interim report, if expected

Planned: 10/04/2020

Date of final study report

Planned: 29/05/2020

Sources of funding

Other

More details on funding

Spanish Society of Hospital Pharmacy

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable